Asia Pacific Allergy Immunotherapies Market is expected to reach US$ 871.08 Mn by 2027

Sublingual Immunotherapy (SLIT) segment by treatment is estimated to lead the market growth during the forecast period

According to The Insight Partners market research study of “Asia Pacific Allergy Immunotherapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Treatment, Allergy type and Distribution Channel,”

The Asia-Pacific allergy Immunotherapies Market was valued at US$ 365.47 million in 2019 and is projected to reach US$ 871.08 million by 2027; it is expected to grow at a CAGR of 11.5% during the forecast period. The strong presence of leading companies in emerging Asian markets and investments for enhancement of SLIT, standardization of dosage, and evaluation of long-term outcomes can be attributed to the market growth.

Based on the treatment, the Asia Pacific allergy immunotherapies market is further segmented into the SCIT segment held a larger share of the market in 2079. However, the SLIT segment is expected to grow at a higher CAGR during the forecast period. Allergen immunotherapy is a medical treatment useful for environmental allergies, insect bite allergies, and asthma. Positive results of various immunotherapies that are in clinical trials encourage the development activities of allergy immunotherapy-based drugs.  The market players are also adopting business expansion, collaboration, and new product development strategies to increase their market footprint.

Forming an excellent regulatory scenario for the sale of drugs through online pharmacies will boost allergy immunotherapy business growth and development. The growing unmet needs of novel targeted drugs, which are used to treat the allergic conditions, will create growth opportunities for the market players. Many companies are investing in research and development to develop targeted drugs for various allergic disorders. To increase their share in the market, companies are introducing more and more allergen immunotherapy tablets (AITs) in potential markets.

Celsion Corporation, World Allergy Organization (WAO), Asia Pacific Association of Allergy and Asthma and Clinical Immunology (APAACI) are among the leading companies operating in the Asia Pacific Allergy Immunotherapy market.     

Asia Pacific Allergy Immunotherapies Market, By Country, 2019 & 2027 (% share)

---

Asia Pacific Allergy Immunotherapies Market to Grow at a CAGR of 11.5 % to reach US$ 871.08 Million from 2020 to 2027

Download Free Sample

---

Asia Pacific Allergy Immunotherapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), Allergy Type (Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and Geography

The report segments Asia Pacific Allergy Immunotherapies Market as follows:

Market Segmentation

By Treatment

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)

By Allergy Type

• Allergic Rhinitis
• Asthma
• Food Allergy
• Venom Allergy
• Others 

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy

By Country

• China
• Japan
• India
• Australia
• South Korea